News
Clinical Trials Arena on MSN21h
Ascletis’s daily acne tablet set for China review after Phase III winThe Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback